Cardio Diagnostics Holdings Inc (CDIO)vsVertex Pharmaceuticals Inc (VRTX)
CDIO
Cardio Diagnostics Holdings Inc
$1.58
+1.28%
HEALTHCARE · Cap: $4.82M
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 73780093% more annual revenue ($12.22B vs $16,560). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
CDIO
Avoid33
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+50.0%
Fair Value
$2.64
Current Price
$1.58
$1.06 discount
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 185.1% year-over-year
Conservative balance sheet, low leverage
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : CDIO
The strongest argument for CDIO centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 185.1% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : CDIO
The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
CDIO profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
CDIO carries more volatility with a beta of 2.18 — expect wider price swings.
CDIO is growing revenue faster at 185.1% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 33/100), backed by strong 35.5% margins. CDIO offers better value entry with a 50.0% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cardio Diagnostics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cardio Diagnostics Holdings Inc (CDIO) is an innovative biotechnology company dedicated to improving cardiovascular health through advanced diagnostic solutions. By harnessing cutting-edge technology, CDIO provides healthcare professionals with essential tools for accurate assessment and effective management of cardiovascular diseases, ultimately enhancing patient outcomes. With a strong focus on personalized medicine, the company is strategically poised for substantial growth, representing a compelling investment opportunity for institutional investors aiming to leverage advancements in the evolving healthcare landscape.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?